Poniard Pharmaceuticals and AltheaDx Sign Agreement
News Apr 15, 2008
Although platinum-based therapy is the standard of care for a broad range of solid tumors, its efficacy in most cancers is limited by the development of platinum resistance. Picoplatin, Poniard's lead product candidate, is a new generation platinum agent designed to overcome platinum resistance. The development of molecular signatures of platinum resistance may allow the prediction of clinical response to picoplatin treatment and may improve outcomes for patients with platinum-resistant cancers.
"We hope to better understand some of the biological mechanisms behind cancer's resurgence after platinum treatment, a significant treatment limiting problem for many patients with solid tumors," said Jerry McMahon, Chairman and CEO of Poniard Pharmaceuticals. "AltheaDx's high throughput gene expression platform facilitates the identification of molecular signature of platinum resistance that can guide therapeutic choices."
"Our mission at AltheaDx is to bring cancer diagnostics into clinical use," said David Macdonald, CEO of AltheaDx. "We are excited about Poniard's choice of our Express Pathway program to expedite identification, validation, and delivery of clinically valid molecular biomarkers to help guide more informed therapeutic decisions."
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE